Azienda Ospedaliera San'Anna e San Sebastiano di Caserta

The Oncoematologia department at Azienda Ospedaliera San'Anna e San Sebastiano di Caserta is conducting research focused on patients with atrial fibrillation who have undergone percutaneous coronary intervention with drug‑eluting stents.

• Evaluating a simplified antithrombotic regimen that begins with a P2Y12 inhibitor followed by long‑term anticoagulation.
• Comparing bleeding risk and major cardiac or cerebral events against standard triple therapy.
• Monitoring safety outcomes over a 15‑month follow‑up period.

This work aims to improve post‑PCI management for heart rhythm patients while reducing complications.

In the same department, investigators are studying metastatic colorectal cancer with RAS mutations to explore new therapeutic options.

• Assessing the anti‑tumor activity of regorafenib as a second‑line treatment.
• Measuring progression‑free survival at six months as a marker of effectiveness.
• Selecting patients with favorable prognostic features for enrollment.

The goal is to expand treatment choices for advanced colorectal cancer patients and improve disease control.